Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commencement of dealings

19 Sep 2006 07:02

Quintessentially English PLC19 September 2006 QUINTESSENTIALLY ENGLISH PLC ("QE" OR THE "COMPANY") COMMENCEMENT OF DEALINGS Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC)announces that it has completed inter alia the acquisition of Omega DiagnosticsLimited, a £1 million placing of new ordinary shares and an issue of warrants toexisting shareholders in the Company. Its ordinary shares are due to bereadmitted to trading on AIM today. Highlights • Acquisition of Omega Diagnostics Limited, a UK company specialising in in-vitro diagnostics test kits and related products through a distribution network in more than 100 countries • £1 million new equity (before expenses) raised via a cash placing of 50,000,000 New Ordinary Shares at 2p per share • Issue of 5,588,432 QE Warrants to existing Shareholders to subscribe for Ordinary Shares at an exercise price of 2p per share • Appointment of a new management team from Omega Diagnostics Limited: Andrew Shepherd, Chief Executive, Kieron Harbinson, Finance Director, David Evans, Non-executive Chairman; Michael Gurner continues as a Non-executive Director • The Acquisition furthers Omega's strategy to become a leading in-vitro diagnostics company - its strategy is to grow through selective acquisitions Andrew Shepherd, Chief Executive, commented: "The purchase of Omega Diagnostics Limited continues our aim to acquirecompanies within the medical diagnostics sector and positions us as a key playerin the in-vitro diagnostics kit market. Our strategy is to grow by acquisitionand to build our portfolio of products which we are already distributingthroughout the UK and in over 100 countries worldwide." On completion, the Company will be paying a maximum consideration of £3 millionof which approximately £1.2 million will be satisfied by the issue of 60,600,000 New Ordinary Shares and the balance of up to approximately £1.8 million as deferred consideration to be satisfied by way of up to 89,400,000 Earn Out Shares at a minimum issue price of 2p per share subject to certain earn out targets being met for the financial year ending 31 March 2008. Immediately following admission, the issued share capital of the Company will be 121,776,865 Ordinary Shares. For further information, please contact: Quintessentially English PLC (to be re-named Omega Diagnostics Group PLC) - 01259 763 030 Andrew ShepherdChief Executive Kieron HarbinsonFinance Director City Financial Associates Limited - 020 7090 7800 Barry SaintDirector END This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Nov 201412:55 pmRNSCorrection: Director's Dealing
28th Nov 201410:35 amRNSDirector's Dealing
28th Nov 20147:00 amRNSDirector's Dealing
26th Nov 20147:00 amRNSHalf Yearly Report
24th Oct 20147:00 amRNSTrading Update and Notice of Interim Results
28th Aug 201412:39 pmRNSResult of AGM
1st Jul 20147:00 amRNSmHealth partnership in Sub-Saharan Africa
23rd Jun 20147:00 amRNSFinal Results
14th Apr 20147:00 amRNSTrading Update and Notice of Results
24th Mar 20144:34 pmRNSDirector/PDMR Shareholding
5th Mar 20142:38 pmRNSDirector/PDMR Shareholding
4th Mar 20143:07 pmRNSHolding(s) in Company
3rd Mar 201411:30 amRNSHolding(s) in Company
28th Feb 201412:42 pmRNSHolding(s) in Company
25th Feb 201411:38 amRNSGrant of Options
25th Feb 201410:06 amRNSCD4 - Grant of ARIPO Patent
24th Feb 20147:00 amRNSAllergy Development Update
24th Feb 20147:00 amRNSCD4 - UNITAID Grant Funding
21st Feb 20142:55 pmRNSHolding(s) in Company
13th Feb 20147:00 amRNSSuccessful completion of CD4 Technology Transfer
20th Dec 20137:00 amRNSCD4 Update
17th Dec 201310:27 amRNSHolding(s) in Company
27th Nov 20137:00 amRNSInterim Results
31st Oct 20137:00 amRNSCD4 Update
17th Oct 20137:00 amRNSTrading Update and Notice of Interim Results
26th Sep 20137:00 amRNSCD4 Update
28th Aug 201311:59 amRNSResult of AGM
17th Jul 201312:10 pmRNSHolding(s) in Company
15th Jul 201311:58 amRNSDirector/PDMR Shareholding
4th Jul 201311:22 amRNSGrant of Options
3rd Jul 20132:21 pmRNSHolding(s) in Company
1st Jul 20137:00 amRNSFinal Results
21st Jun 20137:00 amRNSAllergy Development Update
17th Jun 201310:03 amRNSHolding(s) in Company
10th Jun 201312:18 pmRNSResult of GM
24th May 20137:00 amRNSFundraising to raise £4 million
23rd Apr 20137:00 amRNSGrant of US Patent
22nd Apr 20137:00 amRNSDirectorate Change
10th Apr 20137:00 amRNSTrading Update and Notice of Results
10th Apr 20137:00 amRNSDistribution Agreement
4th Mar 20137:00 amRNSChange of Adviser
17th Dec 20127:00 amRNSChina approves Registration of Food Detective
13th Dec 20127:00 amRNSBanking Facilities increased
3rd Dec 20124:17 pmRNSHolding(s) in Company
21st Nov 20127:00 amRNSHalf Yearly Report
19th Nov 20127:00 amRNSGrant funding award
15th Oct 20127:00 amRNSAgreement with Super Religare Laboratories
15th Oct 20127:00 amRNSTrading Update & Notice of Results
28th Aug 201211:49 amRNSResult of AGM
23rd Jul 20127:00 amRNSPublication of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.